newsfilter
← Latest News
GlobeNewswire·

Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Advanced to the highest dose level in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancersPresented updated preclinical activity of BDC-4182 and key learnings from Phase 1